Fact CheckerSign in

NCT06398743Active, not recruiting

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

Source: ClinicalTrials.gov · Last updated 24 Jul 2025

Brief summary (registry, in English)

The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
416 (actual)
First submitted
24 Apr 2024
Start date
20 Jun 2023
Primary completion date
Sept 2027
Lead sponsor
Exact Sciences Corporation
NCT number
NCT06398743

What you commit to

  • Study type: Observational
  • Participants enrolled: 416
  • From 20 Jun 2023 to the primary completion date, Sept 2027
  • 22 sites in 5 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Initiated adjuvant therapy for current CRC diagnosis (note: neoadjuvant therapy acceptable).
  • Prior history of any invasive cancer (including CRC) within the past 3 years prior to informed consent, with the exception of non-melanoma skin cancer. Patients with a prior history of noninvasive (in situ) carcinomas may participate after definitive treatment.
  • Prior transplant history:
    • Prior allogeneic hematopoietic stem cell transplant at any time.
    • Prior solid organ transplant within the last 2 years prior to enrollment.

Other illness

  • Multiple cancer diagnoses: Synchronous or asynchronous diagnoses (or suspicion) of multiple primary cancers at the time of eligibility screening.

Other

  • Subject is/has:
  • Known pregnancy or breastfeeding at time of enrollment.

Who the study is looking for

  • Subject is/has:
  • 18 years of age or older.
  • Diagnosis of carcinoma of the colon or rectum (patients with lymphomatous, sarcomatous,or neuroendocrine features are not eligible).
  • Post complete surgical resection of CRC, with last surgery occurring within 180 days prior to enrollment are eligible if all of the following conditions are met:
    • in the opinion of the surgeon, all grossly visible tumor was completely resected ("curative resection") and
    • histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells.
    • Patients with T4 tumors that have involved an adjacent structure (e.g., bladder, small intestine, ovary, etc.) by direct extension form the primary tumor must have had all or a portion of the adjacent structure removed en bloc with the primary tumor and local radiation therapy will not be utilized.
  • Pathologic Stage II or III CRC.
  • ECOG performance status ≤ 2 (0, 1 or 2).
  • Able to understand and provide written informed consent.
  • Willing and able to comply with the study requirements, which includes the collection of approximately 35mL of blood for each research blood draw.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (22)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Universitario La Paz
Coordinator of this site? Confirm its status
MadridSpainUnknown status
Centro Integral Oncológico Clara Campal (HM CIOCC)
Coordinator of this site? Confirm its status
MadridSpainUnknown status
Queen Elizabeth Hospital Birmingham
Coordinator of this site? Confirm its status
BirminghamUnited KingdomUnknown status
Edinburgh Cancer Centre
Coordinator of this site? Confirm its status
EdinburghUnited KingdomUnknown status
Churchill Hospital
Coordinator of this site? Confirm its status
HeadingtonUnited KingdomUnknown status
Ipswich Hospital
Coordinator of this site? Confirm its status
IpswichUnited KingdomUnknown status
Kidderminster Hospital and Treatment Centre
Coordinator of this site? Confirm its status
KidderminsterUnited KingdomUnknown status
Alexandra Hospital
Coordinator of this site? Confirm its status
RedditchUnited KingdomUnknown status
Torbay Hospital
Coordinator of this site? Confirm its status
TorquayUnited KingdomUnknown status
Worcestershire Royal Hospital
Coordinator of this site? Confirm its status
WorcesterUnited KingdomUnknown status
Haemek Medical Center
Coordinator of this site? Confirm its status
AfulaIsraelUnknown status
Soroka University Medical Center
Coordinator of this site? Confirm its status
BeershebaIsraelUnknown status
Hillel Yaffe Medical Center
Coordinator of this site? Confirm its status
HaderaIsraelUnknown status
Shaare Zedek Medical Center Jerusalem
Coordinator of this site? Confirm its status
JerusalemIsraelUnknown status
Hadassah University Hospital - Mount Scopus
Coordinator of this site? Confirm its status
JerusalemIsraelUnknown status
Tel Aviv Sourasky Medical Center
Coordinator of this site? Confirm its status
Tel Aviv YaffoIsraelUnknown status
ASST Grande Ospedale Metropolitano Niguarda
Coordinator of this site? Confirm its status
MilanItalyUnknown status
Istituto Nazionale Tumori Fondazione G. Pascale
Coordinator of this site? Confirm its status
NaplesItalyUnknown status
Istituto Clinico Humanitas
Coordinator of this site? Confirm its status
RozzanoItalyUnknown status
National Cancer Center Hospital East
Coordinator of this site? Confirm its status
KashiwaJapanUnknown status
Kagawa University Hospital
Coordinator of this site? Confirm its status
Kita-gunJapanUnknown status
Hokkaido Cancer Center
Coordinator of this site? Confirm its status
SapporoJapanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.